Supernus Pharma (SUPN) Tops Q3 EPS by 44c, Revenues Beat; Raises FY20 Revenue Guidance Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. TENB
6. EBAY
7. CMG
8. KLAC
9. GOOG
10. BIIB

Go back to Supernus Pharma (SUPN) Tops Q3 EPS by 44c, Revenues Beat; Raises FY20 Revenue Guidance Above Consensus

Supernus Announces Third Quarter 2020 Financial Results

November 3, 2020 4:30 PM EST

Q3 2020 total revenues of $155.1 million, including net product sales of $152.1 million and royalty revenues of $3.0 millionQ3 2020 operating earnings of $56.1 millionOn track to initiate commercial launch of SPN-812 in January 2021, if approved by the FDATopline data from the SPN-812 Phase III trial in adult ADHD patients expected in Q1 2021Submitted SPN-830 (Apomorphine infusion pump) NDA to the FDA in September 2020Increased full year 2020 net product sales guidance range of $500 million to $525 million, and operating earnings guidance range of $145 million to $160 million

ROCKVILLE, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:... More